Category: Technology Transfer

Technology Transfer

Researchers Repair Faulty Brain Circuits Using Nanotechnology

Researchers Repair Faulty Brain Circuits Using Nanotechnology

Aug. 21, 2019

The following was originally published in Johns Hopkins Medicine’s Newsroom.

Working with mouse and human tissue, Johns Hopkins Medicine researchers report new evidence that a protein pumped out of some — but not all — populations of “helper” cells in the brain, called astrocytes, plays a specific role in directing the formation of connections among neurons needed for learning and forming new memories.

Using mice genetically engineered and bred with fewer such connections, the researchers conducted proof-of-concept experiments that show they could deliver corrective proteins via nanoparticles to replace the missing protein needed for “road repairs” on the defective neural highway.

Red 8.3 astrocytes in the spine of a mouse. (Courtesy of the Rothstein Lab.)

Since such connective networks are lost or damaged by neurodegenerative diseases such as Alzheimer’s or certain types of intellectual disability, such as Norrie disease, the researchers say their findings advance efforts to regrow and repair the networks and potentially restore normal brain function.The findings are described in the May issue of Nature NeuroscienceThe technology is available for licensing through Johns Hopkins Technology Ventures.

“We are looking at the fundamental biology of how astrocytes function, but perhaps have discovered a new target for someday intervening in neurodegenerative diseases with novel therapeutics,” says  Jeffrey Rothstein, M.D., Ph.D., the John W. Griffin Director of the Brain Science Institute and professor of neurology at the Johns Hopkins University School of Medicine.

“Although astrocytes appear to all look alike in the brain, we had an inkling that they might have specialized roles in the brain due to regional differences in the brain’s function and because of observed changes in certain diseases,” says Rothstein. “The hope is that learning to harness the individual differences in these distinct populations of astrocytes may allow us to direct brain development or even reverse the effects of certain brain conditions, and our current studies have advanced that hope.”

In the brain, astrocytes are the support cells that act as guides to direct new cells, promote chemical signaling, and clean up byproducts of brain cell metabolism.

Rothstein’s team focused on a particular astrocyte protein, glutamate transporter-1, which previous studies suggested was lost from astrocytes in certain parts of brains with neurodegenerative diseases. Like a biological vacuum cleaner, the protein normally sucks up the chemical “messenger” glutamate from the spaces between neurons after a message is sent to another cell, a step required to end the transmission and prevent toxic levels of glutamate from building up.

When these glutamate transporters disappear from certain parts of the brain –such as the motor cortex and spinal cord in people with amyotrophic lateral sclerosis (ALS) –glutamate hangs around much too long, sending messages that overexcite and kill the cells.

To figure out how the brain decides which cells need the glutamate transporters, Rothstein and colleagues focused on the region of DNA in front of the gene that typically controls the on-off switch needed to manufacture the protein. They genetically engineered mice to glow red in every cell where the gene is activated.

Normally, the glutamate transporter is turned on in all astrocytes. But, by using between 1,000- and 7,000-bit segments of DNA code from the on-off switch for glutamate, all the cells in the brain glowed red, including the neurons. It wasn’t until the researchers tried the largest sequence of an 8,300-bit DNA code from this location that the researchers began to see some selection in red cells. These red cells were all astrocytes but only in certain layers of the brain’s cortex in mice.

Because they could identify these “8.3 red astrocytes,” the researchers thought they might have a specific function different than other astrocytes in the brain. To find out more precisely what these 8.3 red astrocytes do in the brain, the researchers used a cell-sorting machine to separate the red astrocytes from the uncolored ones in mouse brain cortical tissue, and then identified which genes were turned on to much higher than usual levels in the red compared to the uncolored cell populations. The researchers found that the 8.3 red astrocytes turn on high levels of a gene that codes for a different protein known as Norrin.

Rothstein’s team took neurons from normal mouse brains, treated them with Norrin, and found that those neurons grew more of the “branches” — or extensions — used to transmit chemical messages among brain cells. Then, Rothstein says, the researchers looked at the brains of mice engineered to lack Norrin, and saw that these neurons had fewer branches than in healthy mice that made Norrin.

In another set of experiments, the research team took the DNA code for Norrin plus the 8,300 “location” DNA and assembled them into deliverable nanoparticles. When they injected the Norrin nanoparticles into the brains of mice engineered without Norrin, the neurons in these mice began to quickly grow many more branches, a process suggesting repair to neural networks. They repeated these experiments with human neurons too.

Rothstein notes that mutations in the Norrin protein that reduce levels of the protein in people cause Norrie disease — a rare, genetic disorder that can lead to blindness in infancy and intellectual disability. Because the researchers were able to grow new branches for communication, they believe it may one day be possible to use Norrin to treat some types of intellectual disabilities such as Norrie disease.

For their next steps, the researchers are investigating if Norrin can repair connections in the brains of animal models with neurodegenerative diseases, and in preparation for potential success, Miller and Rothstein have submitted a patent for Norrin.

Other authors of the publication are Sean Miller, Thomas Philips, Namho Kim, Raha Dastgheyb, Zhuoxun Chen, Yi-Chun Hsieh, J. Gavin Daigle,  Jeannie Chew, Svetlana Vidensky, Jacqueline Pham, Ethan Hughes, Michael Robinson, Rita Sattler, Jung Soo Suk, Dwight Bergles, Norman Haughey, Mikhail Pletnikov and Justin Hanes of Johns Hopkins, and Malika Datta and Raju Tomer of Columbia University.

This work was funded by grants from the National Science Foundation Graduate Fellowship Research Program and the National Institute of Neurological Disorders and Stroke (R01NS092067, R01NS094239).

Startups

From Research to Startup: Why This Johns Hopkins Professor…

From Research to Startup: Why This Johns Hopkins
Professor Became an Entrepreneur

Aug. 12, 2019

Venu Raman’s approach to science is to “see what the data comes to.” So when a drug he built from the ground up showed promising signs as a first-in-class cancer treatment, he decided to launch his own startup.

“This is one of the best things I can do,” says Raman, a professor in the Department of Radiology and Radiological Science and Department of Oncology.

Venu Raman

Raman founded Natsar Pharmaceuticals in early 2016 and, without formal business training, raised $1 million in little over a year and more than $3 million by 2018. The company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration and is aiming for a Phase 1 patient trial next year.

Natsar has developed a compound called RK-33 that inhibits DDX3, an RNA helicase essential for cancer cell proliferation. In testing on mice, RK-33 has been found to increase sensitivity to radiation and treat some of the most resilient cancers — breast, lung and sarcomas.

Raman worked with Johns Hopkins Technology Ventures to secure three patents.

“Without Johns Hopkins Technology Ventures, I couldn’t do this at all,” he says.

Raman also got business help from Katy Kuipers, a former pharmaceutical executive and consultant who provided connections to business leaders. Kuipers helped develop Raman’s business plan and got him in front of investors. She was so impressed with Raman’s work that she joined Natsar last year as vice president of business development and commercial planning.

“I liked that he had already interrogated the target and had many publications,” she says. “He really understands what he’s working with.”

Kuipers, who has seen many small companies pitch to Big Pharma, said Raman is good at explaining his work and answering investors’ questions. Most importantly, she says, Raman also can articulate his vision for Natsar.

“A patent and no plan is no good,” she says.

Five years from now, Kuipers says, she hopes RK-33 has a commercialization partner and is approved in its first cancer indication while being explored in a half-dozen additional types of cancers. Raman, meanwhile, has already thought about his eventual exit strategy from Natsar, whose name combines the first three letters of his daughters’ names. Any potential buyer, he says, must agree to keep the cost to consumers as low as possible.

“Our thought process from day one was to help patients,” he says.

Although Raman spends much of his weekends on the phone with investors, manufacturers and board members, he says it has been satisfying to see the project move toward a clinical trial. He hopes his work will inspire other inventors at Johns Hopkins who might not be sure about going into business.

“If they have the will and they have the data, it’s hard work but it can be done,” he says. “If you’re passionate enough, it can work out.”

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien